These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 8101237

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Ziesche S, Cobb FR, Cohn JN, Johnson G, Tristani F.
    Circulation; 1993 Jun; 87(6 Suppl):VI56-64. PubMed ID: 8500241
    [Abstract] [Full Text] [Related]

  • 6. [Vasodilator agents in chronic heart failure: which is the best option?].
    Corbalán R, Kunstmann S, Jalil J.
    Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172
    [Abstract] [Full Text] [Related]

  • 7. Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
    Cohn JN.
    Herz; 1991 Sep; 16 Spec No 1():267-71. PubMed ID: 1820292
    [Abstract] [Full Text] [Related]

  • 8. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial.
    Ghali JK, Tam SW, Ferdinand KC, Lindenfeld J, Sabolinski ML, Taylor AL, Worcel M, Curry CL, Cohn JN, A-HeFT Investigators.
    Am J Cardiovasc Drugs; 2007 Sep; 7(5):373-80. PubMed ID: 18041162
    [Abstract] [Full Text] [Related]

  • 9. [Modern vasodilator medication in refractory cardiac insufficiency].
    Stanciu L, Branea I, Riviş I, Radivoievici A, Mancaş S, Păunescu A.
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1983 Sep; 35(2):129-34. PubMed ID: 6139858
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Afterload reduction in the treatment of cardiac failure.
    Mason DT.
    Schweiz Med Wochenschr; 1978 Nov 04; 108(44):1695-703. PubMed ID: 102028
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Cardiac failure and nitrates].
    Galinier M, Bounhoure JP.
    Ann Cardiol Angeiol (Paris); 1997 Nov 04; 46(7):415-9. PubMed ID: 9452775
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. The V-HeFT VA Cooperative Studies Group.
    Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G.
    Circulation; 1993 Jun 04; 87(6 Suppl):VI24-31. PubMed ID: 8500236
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of cardiac failure with vasodilators (author's transl)].
    Imhof P.
    Schweiz Rundsch Med Prax; 1978 May 30; 67(22):219-29. PubMed ID: 418395
    [No Abstract] [Full Text] [Related]

  • 19. [Vasodilator agents in the treatment of heart failure].
    Prati PL, Manfrin M.
    G Ital Cardiol; 1978 May 30; 8(1):1-11. PubMed ID: 415927
    [No Abstract] [Full Text] [Related]

  • 20. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K.
    Am J Cardiovasc Drugs; 2002 May 30; 2(1):1-6. PubMed ID: 14727993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.